IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report)'s stock had its "overweight" rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Monday,Benzinga reports.

IDYA has been the topic of a number of other research reports. Stephens initiated coverage on shares of IDEAYA Biosciences in a research report on Monday, November 18th. They issued an "overweight" rating and a $51.00 target price on the stock. Wedbush reaffirmed an "outperform" rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Oppenheimer restated an "outperform" rating and set a $53.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Leerink Partnrs lowered shares of IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IDEAYA Biosciences currently has an average rating of "Moderate Buy" and a consensus price target of $53.67.

IDEAYA Biosciences Price Performance

IDYA traded down $1.06 during trading on Monday, hitting $22.97. 652,316 shares of the stock traded hands, compared to its average volume of 836,659. The business has a 50 day moving average price of $26.89 and a 200 day moving average price of $32.64. The company has a market cap of $1.99 billion, a price-to-earnings ratio of -9.86 and a beta of 0.82. IDEAYA Biosciences has a twelve month low of $22.33 and a twelve month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same quarter last year, the business posted ($0.46) EPS. On average, equities research analysts predict that IDEAYA Biosciences will post -2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IDYA. Allworth Financial LP lifted its position in IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company's stock worth $29,000 after buying an additional 800 shares in the last quarter. Covestor Ltd grew its stake in IDEAYA Biosciences by 23,050.0% in the 3rd quarter. Covestor Ltd now owns 926 shares of the company's stock valued at $29,000 after buying an additional 922 shares during the last quarter. Quest Partners LLC acquired a new position in IDEAYA Biosciences in the 2nd quarter valued at $41,000. US Bancorp DE grew its stake in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company's stock valued at $54,000 after buying an additional 689 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its stake in IDEAYA Biosciences by 637.9% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company's stock valued at $68,000 after buying an additional 1,684 shares during the last quarter. Institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.